CYLD抗体;CYLD Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using CYLD mouse mAb (green) and negative control (red).    

  
  

The CYLD antibody is a crucial tool in studying the cylindromatosis (CYLD) protein, a tumor suppressor encoded by the CYLD gene. Initially identified through its association with familial cylindromatosis, a condition causing benign skin tumors, CYLD functions as a deubiquitinating enzyme (DUB) that regulates key signaling pathways, including NF-κB, Wnt/β-catenin, and JNK. By removing ubiquitin chains from specific substrates, CYLD modulates inflammatory responses, cell proliferation, and apoptosis. Dysregulation of CYLD is linked to various cancers (e.g., skin, renal, and colorectal cancers) and inflammatory disorders, underscoring its role in maintaining cellular homeostasis.

CYLD antibodies are widely used in research to detect CYLD expression and localization via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies help elucidate CYLD's molecular interactions, post-translational modifications, and tissue-specific functions. Recent studies also explore CYLD's involvement in immune regulation, autophagy, and DNA damage repair. Commercial CYLD antibodies are typically validated for specificity and sensitivity, though variability in performance across experimental conditions necessitates careful optimization. Overall, CYLD antibodies remain indispensable for unraveling the protein's dual roles in tumor suppression and immune signaling, offering insights into therapeutic targets for CYLD-associated diseases.